The role of religious leaders and faith organisations in haemoglobinopathies: a review.
BACKGROUND
Sickle cell disease (SCD) is now the most common genetic condition in the world including the UK with an estimate of over 12,500 affected people and over 300 new births per year. Blood transfusion therapy plays a very important role as a disease-modifying strategy in severe SCD e.g. primary and secondary stroke prevention and other acute life-threatening complications such as acute chest infections and acute multi-organ failure. Blood transfusion, however, carries a number of risks including alloimmunisation. There is the need to increase the level of awareness and education about SCD and also to increase blood donation drive among affected communities. These communities are mostly ethnic minority populations who are recognised to have poor access to health care services. Due to the strong impact of religion on these populations, faith organisations may provide potential access for health promotion and interventions.


METHODS
A literature search was conducted to find studies published between 1990-2008 aimed at examining the influence of religious leaders and faith organisations in health, with particular reference to haemoglobinopathies.


RESULTS
Eleven studies were reviewed covering a variety of health interventions. The findings suggest that involvement of religious leaders and faith organisations in health related interventions improved the level of acceptance, participation and positive health outcomes within the faith communities.


CONCLUSIONS
Religious leaders and faith organisations have the potential to influence health education, health promotion and positive health outcomes amongst members of their faith community. They also provide potential access to at-risk populations for increasing awareness about SCD, encouraging health service utilization and ethnic blood donor drives.
Toni-Uebari
Thelma K
TK
Paediatrics Department, West Middlesex University Hospital, Isleworth, Middlesex, UK. thelma2@ntlworld.com
Inusa
Baba P D
BP
J Med Screen. 2008;15(1):9-13
18416948
Transfusion. 2007 Mar;47(3):402-9
17319819
Prenat Diagn. 2001 Jun;21(6):448-51
11438947
Transfusion. 2002 Jun;42(6):684-90
12147019
Public Health Rep. 2001;116 Suppl 1:68-81
11889276
Hum Immunol. 2000 Aug;61(8):834-40
10980395
Immunohematology. 2006;22(3):101-2
17105355
Am J Hematol. 2005 Mar;78(3):198-202
15726598
Transfusion. 2009 Mar;49(3):519-23
19040492
Prenat Diagn. 2000 May;20(5):378-83
10820404
Prenat Diagn. 2006 Sep;26(9):801-9
16927359
Immunohematology. 2006;22(3):112-6
17105358
Soc Sci Med. 1995 Aug;41(3):433-6
7481937
Public Health Nurs. 2007 Jan-Feb;24(1):6-17
17214648
Immunohematology. 2006;22(3):126-31
17105361
Int J Epidemiol. 1993 Aug;22(4):660-5
8225740
Am J Public Health. 2004 Jun;94(6):1030-6
15249311
Arch Dis Child. 2002 May;86(5):325-9
11970920
J Biosoc Sci. 2005 Jan;37(1):115-22
15688575
Transfusion. 2002 Feb;42(2):216-25
11896338
Ethn Dis. 2007 Winter;17(1 Suppl 1):S15-22
17598312
Immunohematology. 2006;22(3):136-42
17105363
J Clin Pathol. 2009 Jan;62(1):26-30
19103854
Am J Public Health. 2002 May;92(5):805-10
11988451
Postgrad Med J. 2005 Mar;81(953):141-7
15749788
Health Educ Behav. 2005 Aug;32(4):536-48
16009749